Carbonic Anhydrase from Porphyromonas Gingivalis as a Drug Target
AbstractPeriodontitis originates from a microbial synergy causing the development of a mouth microbial imbalance (dysbiosis), consisting of a microbial community composed of anaerobic bacteria. Most studies concerning the treatment of periodontitis have primarily take into account the Gram-negative bacterium Porphyromonas gingivalis, because it is a prominent component of the oral microbiome and a successful colonizer of the oral epithelium. Here, we focus our attention on the study of the carbonic anhydrases (CAs, EC 220.127.116.11) encoded in the genome of this pathogen as a possible drug target. Carbonic anhydrases are a superfamily of metalloenzymes, which catalyze the simple but physiologically crucial reaction of carbon dioxide hydration to bicarbonate and protons. Bacterial CAs have attracted significant attention for affecting the survival, invasion, and pathogenicity of many microorganisms. The P. gingivalis genome encodes for two CAs belonging to β-CA (PgiCAβ) and γ-CA (PgiCAγ) families. These two enzymes were cloned, heterologously expressed in Escherichia coli, and purified to homogeneity. Moreover, they were subject to extensive inhibition studies using the classical CA inhibitors (sulfonamides and anions) with the aim of identifying selective inhibitors of PgiCAβ and PgiCAγ to be used as pharmacological tools for P. gingivalis eradication. View Full-Text
Share & Cite This Article
Supuran, C.T.; Capasso, C. Carbonic Anhydrase from Porphyromonas Gingivalis as a Drug Target. Pathogens 2017, 6, 30.
Supuran CT, Capasso C. Carbonic Anhydrase from Porphyromonas Gingivalis as a Drug Target. Pathogens. 2017; 6(3):30.Chicago/Turabian Style
Supuran, Claudiu T.; Capasso, Clemente. 2017. "Carbonic Anhydrase from Porphyromonas Gingivalis as a Drug Target." Pathogens 6, no. 3: 30.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.